Coronavirus (COVID 19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine

As of 1/03/2022, the FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine in order to expand the use of a single booster dose, shorten the time between vaccine completion and booster, and allow for a third primary series dose. Boosters are now available to those that are 12 years and older. The booster interval is now updated to five months for those that are 12 years and older. All children from the ages of 5 to 11 who are immunocompromised have been approved for a third primary series dose if they fulfill the requirements. The booster dose for the authorized vaccines provide better protection from the delta and omicron variants. Most common side effects after receiving the booster shot is as follows: redness and swelling at the injection site, fatigue, headache, and muscle or joint pain and chills.

To learn more, click here.